TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.
Demand for CBD (cannabidiol) products is experiencing strong growth, which we believe
will only accelerate following the recent passage of the Farm Bill. From lotions and balms
in the topicals category to edibles and beverages targeting health and wellness, the
expanding variety of CBD products is matched only by the increase in reasons cited for
their use. With a growing class of companies targeting this opportunity and a looming
regulatory update from the FDA, we thought it timely to take a closer look at everything
In this overview, we offer our detailed forecast for CBD product sales in the US and
review hemp-derived CBD’s current regulatory status. We also examine some of the
science behind CBD’s rise and take inventory of its therapeutic benefits. The hemp CBD
supply chain is fleshed out as well, from the cultivation of hemp and extraction to brands
and retail distribution. In our view, the overall picture that emerges is compelling: despite
lingering FDA uncertainty, we believe CBD’s broad range of therapeutic applications,
dramatically increasing consumer interest, and recent federal legalization in its hempderived form bode well for future growth.
Many of the companies in the Canaccord Genuity coverage universe have meaningful
exposure to the US CBD market. Backgrounds can differ broadly, including companies
focused largely on marijuana and hemp-based consumer-branded products, traditional
multi-state operators (MSOs) primarily intent on building out dispensary networks,
and Canadian LPs developing US-facing revenue streams. For a full discussion of CBD
exposure for covered companies, please refer to page 40 of this document.
Notable content includes a state-level forecast and US estimates that differentiate
between hemp CBD and marijuana CBD channels, an overview of regional US hemp
production, and descriptions of over 30 public and private CBD companies along with
their roles within the emerging supply chain. Following an executive summary and
high-level takeaways, we begin with a discussion of the science underpinning CBD’s
substantial therapeutic promise
We build Industrial Site for Cannabis Oil Extraction. See more at: PHARMAIUM
Continue at: http://stillcanna.com/wp-content/uploads/2019/09/Canaccord-CBD_Report.pdf
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link